Our ApproachWe are on a mission to preserve vision and prevent blindness.
Patients with certain ophthalmic diseases can suffer progressive and permanent vision loss over time. Despite numerous approved therapies, glaucoma remains a leading cause of preventable blindness worldwide. We are committed to combining our expertise in drug development with an undaunted creative approach to develop therapies that others may have overlooked in order to make an unprecedented change for patients with glaucoma and other treatable ophthalmic disorders.
QLS-111
Our lead program, QLS-111, is designed to meet unmet needs with a unique vasodilatory mechanism of action formulated to lower IOP by reducing episcleral venous pressure (EVP). Thanks to this first-in-class mechanism of action, we can now tackle obstacles that were previously considered insurmountable, and we will continue to follow the science to additional indications where there is patient need.
Add Your Heading Text Here
Collaborations
